Home » Business News » 2012 » April » April 10, 2012

Bavarian Nordic Nominates Peter Kürstein for Election to the Board

April 10, 2012 - London

KVISTGAARD, Denmark, April 10, 2012 - Bavarian Nordic A/S (OMX: BAVA) - Following the notice convening the ordinary general meeting, published on 21 March 2012, the board of directors of Bavarian Nordic hereby announces the nomination of a new candidate for election at the general meeting on Monday, 16 April 2012.

The candidate is Peter Kürstein, who is President of Radiometer Medical ApS. He has held managerial positions in Radiometer for many years, the latter eight as President of the company. He has long experience from the boards of larger Danish industrial companies. Peter Kürstein holds an MBA from Harvard Business School in Boston, USA. He is a Danish national and born in 1956.

Peter Kürstein is vice chairman of the board of FOSS A/S and member of the board of Radiometer Medical ApS.  Furthermore he is chairman of the Danish-American Business Forum and the Committee of Healthcare under the Confederation of Danish Industries.

Peter Kürstein will replace Erling Johansen in the board, who upon his own request, has chosen not to be nominated for re-election.

Thus, the candidates for election at the ordinary general meeting are Asger Aamund, Claus Bræstrup, Gerard van Odijk, Anders Gersel Pedersen, Erik G. Hansen and Peter Kürstein.

Asger Aamund
Chairman of the Board

Asger Aamund. Phone +45 40 78 19 11

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE



Comment on this story